CN105747209A - 一种共轭亚油酸微囊剂配方及制备方法 - Google Patents
一种共轭亚油酸微囊剂配方及制备方法 Download PDFInfo
- Publication number
- CN105747209A CN105747209A CN201610099432.1A CN201610099432A CN105747209A CN 105747209 A CN105747209 A CN 105747209A CN 201610099432 A CN201610099432 A CN 201610099432A CN 105747209 A CN105747209 A CN 105747209A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- linoleic acid
- conjugated linoleic
- sulfate
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 title claims abstract description 41
- 229940108924 conjugated linoleic acid Drugs 0.000 title claims abstract description 41
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 title claims abstract description 41
- 239000003094 microcapsule Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims description 12
- 238000009472 formulation Methods 0.000 title description 4
- 239000000843 powder Substances 0.000 claims abstract description 32
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 29
- 239000011782 vitamin Substances 0.000 claims abstract description 27
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 26
- 229940088594 vitamin Drugs 0.000 claims abstract description 26
- 229930003231 vitamin Natural products 0.000 claims abstract description 26
- 235000013343 vitamin Nutrition 0.000 claims abstract description 26
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 15
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 14
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 14
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims abstract description 14
- 239000011790 ferrous sulphate Substances 0.000 claims abstract description 14
- 235000003891 ferrous sulphate Nutrition 0.000 claims abstract description 14
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims abstract description 14
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims abstract description 14
- 235000013336 milk Nutrition 0.000 claims abstract description 14
- 239000008267 milk Substances 0.000 claims abstract description 14
- 210000004080 milk Anatomy 0.000 claims abstract description 14
- 235000015921 sodium selenite Nutrition 0.000 claims abstract description 14
- 229960001471 sodium selenite Drugs 0.000 claims abstract description 14
- 239000011781 sodium selenite Substances 0.000 claims abstract description 14
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 14
- 239000011718 vitamin C Substances 0.000 claims abstract description 14
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 14
- 239000011710 vitamin D Substances 0.000 claims abstract description 14
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 14
- 229940046008 vitamin d Drugs 0.000 claims abstract description 14
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims abstract description 14
- 229960001763 zinc sulfate Drugs 0.000 claims abstract description 14
- 229910000368 zinc sulfate Inorganic materials 0.000 claims abstract description 14
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 13
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 13
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 13
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 13
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 13
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 13
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 13
- 239000011719 vitamin A Substances 0.000 claims abstract description 13
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 13
- 229940045997 vitamin a Drugs 0.000 claims abstract description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 12
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 12
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 12
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 10
- 235000013365 dairy product Nutrition 0.000 claims abstract description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 6
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 5
- 239000011709 vitamin E Substances 0.000 claims abstract description 5
- 229940046009 vitamin E Drugs 0.000 claims abstract description 5
- 229960003563 calcium carbonate Drugs 0.000 claims abstract description 3
- 229960001781 ferrous sulfate Drugs 0.000 claims abstract description 3
- 229960003390 magnesium sulfate Drugs 0.000 claims abstract description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 31
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 24
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- -1 VitAVitE Substances 0.000 claims description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 7
- 239000011575 calcium Substances 0.000 abstract description 7
- 229910052791 calcium Inorganic materials 0.000 abstract description 7
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 5
- 239000011669 selenium Substances 0.000 abstract description 5
- 229910052711 selenium Inorganic materials 0.000 abstract description 5
- 229940091258 selenium supplement Drugs 0.000 abstract description 5
- 229960003495 thiamine Drugs 0.000 abstract description 5
- 239000011701 zinc Substances 0.000 abstract description 5
- 229910052725 zinc Inorganic materials 0.000 abstract description 5
- 238000000354 decomposition reaction Methods 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 229930003451 Vitamin B1 Natural products 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract description 3
- 235000010374 vitamin B1 Nutrition 0.000 abstract description 3
- 229940011671 vitamin b6 Drugs 0.000 abstract description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract description 2
- 229930003779 Vitamin B12 Natural products 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract description 2
- 229960002477 riboflavin Drugs 0.000 abstract description 2
- 235000019163 vitamin B12 Nutrition 0.000 abstract description 2
- 235000019158 vitamin B6 Nutrition 0.000 abstract description 2
- 229930003471 Vitamin B2 Natural products 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 235000019164 vitamin B2 Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 210000003617 erythrocyte membrane Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 229940029329 intrinsic factor Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229930003802 tocotrienol Natural products 0.000 description 2
- 239000011731 tocotrienol Substances 0.000 description 2
- 235000019148 tocotrienols Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- 102000014701 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 206010047631 Vitamin E deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种共轭亚油酸微囊剂配方,包括组分:共轭亚油酸微囊粉;低聚异麦芽糖;植脂末;乳粉;麦芽糊精;碳酸钙;硫酸亚铁;硫酸锌;硫酸镁;亚硒酸钠;维生素C;维生素A;维生素;维生素E;维生素B1;维生素B2;维生素B6;维生素B12。本发明的有益效果是,微囊有效地延缓其分解、氧化、挥发等变质过程,从而保持稳定;靶向定位分解,大大的解决了共轭亚油酸的吸收转化率低的难题;添加了人体所必需的钙、铁、锌、硒和多种维生素达到了补充多种营养目的。
Description
技术领域
本发明涉及共轭亚油酸微囊粉技术领域,尤其涉及一种共轭亚油酸微囊剂配方及制备方法。
背景技术
CLA(共轭亚油酸)是组成脂肪的多种脂肪酸中的一种。既是人和动物不可缺少的脂肪酸之一,又是人和动物无法合成的一种物质,必须从食物中摄取。
目前市场上各种CLA(共轭亚油酸)补充剂很多,但多以软胶囊形式出现,并且含量很低,例如:一些软胶囊产品含CLA≤0.9g/粒,含量极少,这些保健品的不足之处主要体现在:CLA含量低,吸收转化率低,而且软胶囊外皮成分主要为胶料(如明胶),增塑剂(甘油,山梨醇等),添加剂(防腐剂、香料、遮光剂等)和水,吸收转化率为60%左右,所以人体吸收及转化存在较大的难题。
发明内容
本发明所要解决的技术问题是,提供一种共轭亚油酸微囊剂配方及制备方法,微囊有效地延缓其分解、氧化、挥发等变质过程,从而保持稳定;靶向定位分解,大大的解决了共轭亚油酸的吸收转化率低的难题;添加了人体所必需的钙、铁、锌、硒和多种维生素达到了补充多种营养目的。
为实现上述目的,本发明采用下述技术方案:
一种共轭亚油酸微囊剂配方,包括以下重量百分比组分:共轭亚油酸微囊粉40-70%;低聚异麦芽糖3%-8%;植脂末10-30%;乳粉5-15%;麦芽糊精5-15%;碳酸钙0.2-0.6%;硫酸亚铁0.05-0.08‰;硫酸锌0.01-0.04‰;硫酸镁0.001-0.002‰;亚硒酸钠0.0001-0.0002‰;维生素C0.5-2%;维生素A0.05-0.08‰;维生素D0.0007-0.001‰;维生素E0.5-1.5‰;维生素B10.05-0.1‰;维生素B20.05-0.1‰;维生素B60.05-0.1‰;维生素B120.0001-0.00025‰。
一种共轭亚油酸微囊剂配方,包括以下重量百分比组分:共轭亚油酸微囊粉50%,低聚异麦芽8%,植脂末20%,乳粉10%,麦芽糊精10%,碳酸钙0.5%,硫酸亚铁0.06‰,硫酸锌0.02‰,硫酸镁0.001‰,亚硒酸钠0.0002‰,维生素C1.5%,维生素A0.05‰,维生素D0.0007‰,维生素E1.2‰,,维生素B10.09‰,,维生素B20.09‰,,维生素B60.09‰,维生素B120.0002‰。
一种共轭亚油酸微囊剂的制备方法,包括的步骤有:
1、将碳酸钙、硫酸亚铁、硫酸锌、硫酸镁、亚硒酸钠、维生素A、维生素E、维生素D、维生素C、维生素B1、维生素B2、维生素B6、维生素B12混合均匀;
2、将步骤1中混合均匀后的混合物再与共轭亚油酸微囊粉、低聚异麦芽糖、植脂末、乳粉、麦芽糊精一起混合均匀;
3、步骤2中混匀后的混合物置于60-70℃下干燥5小时,并进行灭菌,在净化车间冷却后进行粉剂灌装。
其中,碳酸钙中含钙量高达40%,副作用小,吸收率较高,可以达到与牛奶相似,是人民易于接受而广泛应用的一种钙制剂,碳酸钙是被列入国家药典的钙剂,是中国营养学会首推补钙剂,也是国际上普遍认可的钙制剂。
铁是人体所必需的元素,为红细胞合成血红素必不可少的物质,在众多的铁剂当中,硫酸亚铁由于其不良反应较少,且价格便宜,所以,目前为止它仍是治疗缺铁性贫血的基本药物。
锌是人体必需的微量元素之一,在人体生长发育过程中起着极其重要的作用,硫酸锌为常见的无机锌。
镁是人体不可缺少的矿物质元素之一,镁几乎参与人体所有的新陈代谢过程,在细胞内它的含量仅次于钾,镁影响钾、钠、钙离子细胞内外移动的“通道”,并有维持生物膜电位的作用,镁元素的缺乏必然会对人体健康造成危害。
硒是一种人体需要的微量元素,是人体不可缺少的一种元素,亚硒酸钠为化学无机硒。
维生素A与正常视觉有密切关系,为骨骼正常生长所必需,有助于细胞的增生与生长,并对上皮的正常形成,发育以及维持十分重要。维生素A有延缓或阻止前病变,防止化学性致癌物作用,特别是防止上皮恶性肿瘤的作用。缺乏维生素A引起以眼和皮肤病变为主的全身性疾病,患者以婴幼儿为主,常和营养不良并存,伴随蛋白质-能量营养不良等。
维生素E(vitaminE)是生育酚(tocopherol,T)与三烯生育酚(Tocotrienol,T-3)的总称,是脂溶性维生素,为细胞膜上的重要组成成分,亦是细胞膜上的主要抗氧化剂。当维生素E缺乏时红细胞膜上的PUFA易发生过氧化反应,使红细胞膜受损而产生溶血。
维生素D(vitaminD)是类固醇的衍生物,又可分为维生素D2和维生素D3。维生素D缺乏会导致少儿佝偻病和成年人的软骨病。
维生素C(VitaminC,又称L-抗坏血酸)是高等灵长类动物与其他少数生物的必需营养素。在生物体内,维生素C是一种抗氧化剂,因为它能够保护身体免于氧化剂的威胁。维生素C的药效基团是抗坏血酸离子,最广为人知的是缺乏维生素C会造成坏血病。
维生素B1又名硫胺素。硫胺素在体内的作用在于以羧化酶,转羟乙醛酶系统的辅酶形式参加糖类代谢,是物质代谢和能量代谢中具有关键性的物质基础。维生素B1还参与体内的氧化脱羧作用,为支链氨基酸代谢所必需。此外,维生素B1对促进食欲、胃肠道的正常蠕动和消化液的分泌等也有重要作用。、
维生素B2又叫核黄素,微溶于水,在自然界分布广泛的一种维生素,是哺乳动物必需的营养物,其辅酶形式是黄素单核苷酸和黄素腺嘌呤二核苷酸。当缺乏时,就会影响机体的生物氧化,使代谢发生障碍。
维生素B6(VitaminB6)又称吡哆素,其包括吡哆醇、吡哆醛及吡哆胺,在体内以磷酸酯的形式存在,是一种水溶性维生素。维生素B6为人体内某些辅酶的组成成分,参与多种代谢反应,尤其是和氨基酸代谢有密切关系。
维生素B12又叫钴胺素,是唯一含金属元素的维生素。维生素B12是惟一的一种需要一种肠道分泌物(内源因子)帮助才能被吸收的维生素。有的人由于肠胃异常,缺乏这种内源因子,即使膳食中来源充足也会患恶性贫血。
本发明的有益效果是,
1、本发明的微囊剂肉眼看是粉状,显微镜下是一颗颗油状液体,由特殊的囊材包裹,微囊技术是使用天然或合成的高分子材料,将固体、液体甚至是气体的微小颗粒包裹在半透性或密闭性微胶囊内的一种技术,微囊粒径从微米级到纳米级,与外界环境相隔离,可以免受环境的影响,有效地延缓其分解、氧化、挥发等变质过程,从而保持稳定。
2、微囊剂型的最大优点是靶向定位分解,有效率可提高90%-200%,大大的解决了共轭亚油酸的吸收转化率低的难题。
3、每天所服用的CLA可达到人体所需要的3g标准,人体每日服用本发明复合配方10g可达到该标准。
4、另外复合配方添加了人体所必需的钙、铁、锌、硒和多种维生素,达到了补充人体所需要营养的目的。
具体实施方式
为了能够清楚的说明本方案的技术特点,下面结合实施例对本发明作进一步的说明。
实施例1
一种共轭亚油酸微囊剂配方,包括以下重量百分比组分:共轭亚油酸微囊粉40%;低聚异麦芽糖3%;植脂末30%;乳粉5%;麦芽糊精5%;碳酸钙0.6%;硫酸亚铁0.08‰;硫酸锌0.04‰;硫酸镁0.001‰;亚硒酸钠0.0001‰;维生素C0.5%;维生素A0.05‰;维生素D0.0007‰;维生素E0.5‰;维生素B10.05‰;维生素B20.05‰;维生素B60.05‰;维生素B120.0001‰。
一种共轭亚油酸微囊剂的制备方法,包括的步骤有:
1、将0.6%碳酸钙、0.08‰硫酸亚铁、0.04‰硫酸锌、0.001‰硫酸镁、0.0001‰亚硒酸钠、0.5%维生素C、0.05‰维生素A、0.0007‰维生素D、0.5‰维生素E、0.05‰维生素B1、0.05‰维生素B2、0.05‰维生素B6、0.0001‰维生素B12混合均匀;
2、将步骤1中混合均匀后的混合物再与40%共轭亚油酸微囊粉、3%低聚异麦芽糖、30%植脂末、5%乳粉、5%麦芽糊精一起混合均匀;
3、步骤2中混匀后的混合物置于60-70℃下干燥5小时,并进行灭菌,在净化车间冷却后进行粉剂灌装。
实施例2
一种共轭亚油酸微囊剂配方,包括以下重量百分比组分:共轭亚油酸微囊粉50%,低聚异麦芽8%,植脂末20%,乳粉10%,麦芽糊精10%,碳酸钙0.5%,硫酸亚铁0.06‰,硫酸锌0.02‰,硫酸镁0.001‰,亚硒酸钠0.0002‰,维生素C1.5%,维生素A0.05‰,维生素D0.0007‰,维生素E1.2‰,,维生素B10.09‰,,维生素B20.09‰,,维生素B60.09‰,维生素B120.0002‰。
一种共轭亚油酸微囊剂的制备方法,包括的步骤有:
1、将0.5%碳酸钙、0.06‰硫酸亚铁、0.02‰硫酸锌、0.001‰硫酸镁、0.0002‰亚硒酸钠、0.0007‰维生素C、0.05‰维生素A、0.0007‰维生素D、1.2‰维生素E、0.09‰维生素B1、0.09‰,维生素B2、0.09‰维生素B6、0.0002‰维生素B12混合均匀;
2、将步骤1中混合均匀后的混合物再与50%共轭亚油酸微囊粉、8%低聚异麦芽糖、20%植脂末、20%乳粉、10%麦芽糊精一起混合均匀;
3、步骤2中混匀后的混合物置于60-70℃下干燥5小时,并进行灭菌,在净化车间冷却后进行粉剂灌装。
实施例3
一种共轭亚油酸微囊剂配方,包括以下重量百分比组分:共轭亚油酸微囊粉70%;低聚异麦芽糖8%;植脂末10%;乳粉15%;麦芽糊精5%;碳酸钙0.2%;硫酸亚铁0.05‰;硫酸锌0.01‰;硫酸镁0.002‰;亚硒酸钠0.0002‰;维生素C2%;维生素A0.08‰;维生素D0.001‰;维生素E1.5‰;维生素B10.1‰;维生素B20.1‰;维生素B60.1‰;维生素B120.00025‰。
一种共轭亚油酸微囊剂的制备方法,包括的步骤有:
1、将0.2%碳酸钙、0.05‰硫酸亚铁、0.01‰硫酸锌、0.002‰硫酸镁、0.0002‰亚硒酸钠、2%维生素C、0.08‰维生素A、0.001‰维生素D、1.5‰维生素E、0.1‰维生素B1、0.1‰维生素B2、0.1‰维生素B6、0.00025‰维生素B12混合均匀;
2、将步骤1中混合均匀后的混合物再与70%共轭亚油酸微囊粉、8%低聚异麦芽糖、10%植脂末、15%乳粉、5%麦芽糊精一起混合均匀;
3、步骤2中混匀后的混合物置于60-70℃下干燥5小时,并进行灭菌,在净化车间冷却后进行粉剂灌装。
本发明未经描述的技术特征可以通过现有技术实现,在此不再赘述。当然,上述说明并非是对本发明的限制,本发明也不仅限于上述举例,本技术领域普通技术人员在本发明的实质范围内所作出的变化、改型、添加或更换,也应属于本发明的保护范围。
Claims (3)
1.一种共轭亚油酸微囊剂配方,其特征在于,包括以下重量百分比组分:共轭亚油酸微囊粉40-70%;低聚异麦芽糖3%-8%;植脂末10-30%;乳粉5-15%;麦芽糊精5-15%;碳酸钙0.2-0.6%;硫酸亚铁0.05-0.08‰;硫酸锌0.01-0.04‰;硫酸镁0.001-0.002‰;亚硒酸钠0.0001-0.0002‰;维生素C0.5-2%;维生素A0.05-0.08‰;维生素D0.0007-0.001‰;维生素E0.5-1.5‰;维生素B10.05-0.1‰;维生素B20.05-0.1‰;维生素B60.05-0.1‰;维生素B120.0001-0.00025‰。
2.如权利要求1所述的一种共轭亚油酸微囊剂配方,其特征在于,包括以下重量百分比组分:共轭亚油酸微囊粉50%,低聚异麦芽8%,植脂末20%,乳粉10%,麦芽糊精10%,碳酸钙0.5%,硫酸亚铁0.06‰,硫酸锌0.02‰,硫酸镁0.001‰,亚硒酸钠0.0002‰,维生素C1.5%,维生素A0.05‰,维生素D0.0007‰,维生素E1.2‰,,维生素B10.09‰,,维生素B20.09‰,,维生素B60.09‰,维生素B120.0002‰。
3.如权利要求1或2所述的一种共轭亚油酸微囊剂的制备方法,其特征在于,包括的步骤有:1、将碳酸钙、硫酸亚铁、硫酸锌、硫酸镁、亚硒酸钠、维生素A、维生素E、维生素D、维生素C、维生素B1、维生素B2、维生素B6、维生素B12混合均匀;2、将步骤1中混合均匀后的混合物再与共轭亚油酸微囊粉、低聚异麦芽糖、植脂末、乳粉、麦芽糊精一起混合均匀;3、步骤2中混匀后的混合物置于60-70℃下干燥5小时,并进行灭菌,在净化车间冷却后进行粉剂灌装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610099432.1A CN105747209A (zh) | 2016-02-24 | 2016-02-24 | 一种共轭亚油酸微囊剂配方及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610099432.1A CN105747209A (zh) | 2016-02-24 | 2016-02-24 | 一种共轭亚油酸微囊剂配方及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105747209A true CN105747209A (zh) | 2016-07-13 |
Family
ID=56330299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610099432.1A Pending CN105747209A (zh) | 2016-02-24 | 2016-02-24 | 一种共轭亚油酸微囊剂配方及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105747209A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1357407A (zh) * | 2001-10-24 | 2002-07-10 | 中国科学院新疆化学研究所 | 共轭亚油酸或共轭亚油酸酯的微胶囊 |
CN105077249A (zh) * | 2015-09-06 | 2015-11-25 | 蓬莱海洋(山东)股份有限公司 | 一种共轭亚油酸微胶囊及其制备方法 |
CN105285983A (zh) * | 2015-10-27 | 2016-02-03 | 江西美庐乳业集团有限公司 | 一种帮助减肥、瘦身的营养包 |
-
2016
- 2016-02-24 CN CN201610099432.1A patent/CN105747209A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1357407A (zh) * | 2001-10-24 | 2002-07-10 | 中国科学院新疆化学研究所 | 共轭亚油酸或共轭亚油酸酯的微胶囊 |
CN105077249A (zh) * | 2015-09-06 | 2015-11-25 | 蓬莱海洋(山东)股份有限公司 | 一种共轭亚油酸微胶囊及其制备方法 |
CN105285983A (zh) * | 2015-10-27 | 2016-02-03 | 江西美庐乳业集团有限公司 | 一种帮助减肥、瘦身的营养包 |
Non-Patent Citations (1)
Title |
---|
纵伟: "《食品工业新技术》", 30 April 2006, 东北林业大学出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2009130333A (ru) | Повышение стабильности витаминных и минеральных добавок | |
RU2456000C2 (ru) | Смесь солей железа и меди, маскирующая металлический вкус | |
CN104585835A (zh) | 营养物质添加方法、营养颗粒和含有营养颗粒的食品和饮料 | |
KR20080059564A (ko) | 금속 맛을 차폐한 철 및 구리 염의 혼합물 | |
KR20200016402A (ko) | 연질 캡슐 피막용 조성물 | |
CN101861144B (zh) | 硫辛酸丸状物组合物 | |
CN101564398B (zh) | 一种多维生素软胶囊及其制备方法 | |
CA2582934A1 (en) | Composition containing omega-3 fatty acids and omega-6 fatty acids | |
CN102389076A (zh) | 一种降低胆固醇的组合物及其制备方法 | |
CN108651634A (zh) | 一种适合0到6个月婴儿的配方奶粉及其制备方法 | |
CN105192307A (zh) | 以稳定性为目的的纳米级液体复合维生素氨基酸包被技术 | |
CN102210658B (zh) | 高含量α-亚麻酸微囊软胶囊制剂 | |
JP5432563B2 (ja) | ホスファチジルセリン含有カプセル及びカプセル充填用ホスファチジルセリン組成物 | |
US20220305033A1 (en) | Dietary nutrient compositions | |
WO2018133833A1 (zh) | 稳定的脂溶性活性成分组合物、微囊及其制备方法和应用 | |
CN105747209A (zh) | 一种共轭亚油酸微囊剂配方及制备方法 | |
CN111972589A (zh) | 一种补充维生素a的盐藻粉泡腾片 | |
KR20080008155A (ko) | 한국인에게 특별히 필요한 비타민, 무기질, 또는 발효시킨천연물을 함유하는 영양제 조성물 | |
JP3106534B2 (ja) | 栄養補助食品 | |
TW202114644A (zh) | 口服產品 | |
JP3754625B2 (ja) | 安定化されたユビデカレノン組成物およびユビデカレノン組成物の安定化方法 | |
WO2017076711A1 (en) | A leachable solid composition and process of manufacture thereof | |
RU2527042C1 (ru) | Биологически активная добавка к пище для профилактики заболеваний остеопорозом | |
US20170245533A1 (en) | Fortified Micronutrient Product and Methods of Use and Manufacture | |
KR100832675B1 (ko) | 영양 보조제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160713 |
|
WD01 | Invention patent application deemed withdrawn after publication |